Orchid Pharma Limited has announced that its board meeting is scheduled to be held on Monday, May 25, 2026. The meeting has been convened in accordance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Meeting

The board will consider and approve the audited financial results for the quarter and financial year ending March 31, 2026. The results to be approved include both standalone and consolidated financial statements for Quarter-IV and Financial Year 2025-26.

Trading Window Closure

In continuation of an earlier intimation dated March 27, 2026, regarding the trading window closure period, the company has stated that the window for dealing in its securities has been closed since April 01, 2026. This closure will remain in effect until 48 hours after the declaration of the audited financial results for the quarter ending March 31, 2026.

The intimation was signed by Kapil Dayya, Company Secretary & Compliance Officer of Orchid Pharma Limited .

Orchid pharma has received a favorable ruling from the National Company Law Tribunal (NCLT) Chennai Bench, which dismissed an application filed by DBS Bank regarding lease rent claims during the Corporate Insolvency Resolution Process (CIRP) period. The order was pronounced on April 02, 2026, and made available on the NCLT website on April 10, 2026.

NCLT Order Details

The NCLT Chennai Bench, presided over by Hon'ble Member (Judicial) Shri. Jyoti Kumar Tripathi and Hon'ble Member (Technical) Shri. Ravichandran Ramasamy, dismissed the Interim Application filed by DBS Bank (formerly known as Lakshmi Villas Bank). The application sought relief under multiple sections of the Insolvency and Bankruptcy Code, 2016.

Nature of DBS Bank's Application

DBS Bank (erstwhile Lakshmi Vilas Bank) had filed an Interim Application claiming lease dues for the CIRP period and Insolvency Resolution Process Cost. The bank sought relief under Section 60(5)(a), (b) and (c) read with Sections 30(2) and 53 of the Insolvency and Bankruptcy Code, 2016, along with various regulations under the IBBI (Insolvency Resolution Process for Corporate Persons) Regulations, 2016.

Financial Impact Assessment

Orchid Pharma has disclosed that the NCLT's dismissal of DBS Bank's application has no quantifiable financial impact on the company's operations or other activities. This outcome represents a positive development for the pharmaceutical company, as it eliminates potential financial obligations that could have arisen from the lease rent claims.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This intimation follows an earlier communication dated September 27, 2023, indicating that the legal proceedings have been ongoing for a considerable period.

Court Proceedings

The hearing was conducted through video conferencing on April 02, 2026, at 10:30 AM. The respondent was represented by learned counsel Mr. Kastubh Prakash during the proceedings. The tribunal's decision to dismiss the application marks the conclusion of this particular legal matter in favor of Orchid Pharma.